Drug Profile

Research programme: Alagille syndrome therapeutics - Travere Therapeutics

Latest Information Update: 28 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Retrophin
Developer National Center for Advancing Translational Sciences; Travere Therapeutics
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jul 2023 No recent reports of development identified for preclinical development in Alagille syndrome in USA
16 Nov 2020 Retrophin is now called Travere Therapeutics
18 Jun 2019 Retrophin establishes CRADA with National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the development of compounds in Alagille syndrome

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com